Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNP-TPT
- Development stage
- Preclinical
- Lead developer
- SiNON Nano Sciences
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
01
Overview
**CNP-TPT** is a preclinical carbon-nanoparticle formulation of the small-molecule chemotherapy agent topotecan being developed by SiNON Nano Sciences for cancer. The carbon nanoparticle carrier is intended to encapsulate topotecan and improve delivery, stability, controlled release, and therapeutic exposure. Topotecan inhibits DNA topoisomerase I by stabilizing the topoisomerase I-DNA cleavage complex and preventing DNA strand re-ligation, leading to replication-associated DNA damage and tumor-cell death. ([sinontx.com](https://sinontx.com/product/cnp-arg-copy-2/))
- Other names
- Topotecan encapsulated in Carbon Nano Particles
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on CNP-TPT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNP-TPT.